Clinical Trials Logo

Clinical Trial Summary

The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.


Clinical Trial Description

Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustaining the hair follicle's immune privilege through anti-inflammatory effects such as controlling Interferon gamma (IFN-γ) production. A recent study showed a significant decrease of vitamin D in Black patients with Central Centrifugal Cicatricial Alopecia (CCCA)" ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05416320
Study type Interventional
Source Wake Forest University Health Sciences
Contact
Status Withdrawn
Phase Early Phase 1
Start date August 2023
Completion date December 2023

See also
  Status Clinical Trial Phase
Completed NCT03521687 - Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Phase 4
Not yet recruiting NCT05416333 - Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) Early Phase 1
Recruiting NCT04764331 - A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia N/A
Recruiting NCT05759338 - A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia N/A
Completed NCT03346668 - Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia Early Phase 1
Completed NCT03044782 - Barriers to Care and QOL for CCCA Patients N/A
Completed NCT04342091 - Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling N/A